More news from New York, this time from Long Island. BioSpecifics received fresh cash of $2+ million.
BioSpecifics is an interesting company, and their history is summarized here. Basically, they developed a topical collagenase product, which was then sold. The company then focused on developing parenteral collagenase products for a wide array of indications.
I always find it interesting when a company that appears to have a narrow focus is able to identify seemingly obscure applications and actually move these applications forward in the clinic. That takes diligent research and thought leader insight to identify and assess the ideas, but that's the easy part. The tough part is to then move these into and through trials, especially in indications where there are no products, and hence no "pathways" for companies like this to follow.